Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients

[Guest guest]

http://www.ingentaconnect.com/content/bsc/jvh/2011/00000018/00000005/art00003

Journal of Viral Hepatitis, Volume 18, Number 5

Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV

genotypes in HIV/HCV-coinfected patients

Authors: Medrano, J.1; Resino, S.2; Vispo, E.1; Madejón, A.1; Labarga, P.1;

Tuma, P.1; Martín-Carbonero, L.1; Barreiro, P.1; -Novoa, S.3;

Jiménez-Nacher, I.3; Soriano, V.1

Source: Journal of Viral Hepatitis, Volume 18, Number 5, May 2011 , pp.

325-330(6)

Publisher: Wiley-Blackwell

Abstract:

Summary. 

The efficacy of current hepatitis C therapy in HIV/HCV-coinfected patients is

largely dependent on HCV genotype. The annual prevalence of HCV

genotypes/subtypes and their influence on HCV clearance with antiviral treatment

were examined in a dynamic cohort of HIV/HCV-coinfected patients followed up in

Madrid since 2000. Patients entered the cohort at first visit and left the

cohort when HCV clearance was achieved with HCV therapy or when follow-up was

interrupted for any reason, including death. A total of 672 HIV/HCV-coinfected

patients constituted the cohort. The mean follow-up time was 5.5 years,

corresponding to 4108 patient-years. Mean age at entry was 37 years, and 73%

were men and 86% were intravenous drug users. Overall distribution of HCV

genotypes was as follows: 57.1% HCV-1 (1a: 29.2%, 1b: 20.4%, unknown: 7.6%),

1.3% HCV-2, 25.4% HCV-3 and 15.9% HCV-4. A total of 274 (40.8%) patients were

treated with peginterferon-ribavirin, of whom 116 (42.3%) achieved HCV clearance

following 1-3 courses of therapy. The proportion of HCV-1/4 rose from 71.7% in

2000 to 76.8% in 2008, whereas the proportion of HCV-2/3 fell from 28.1% in 2000

to 23.2% in 2008. The yearly prevalence increased for HCV-1 (R2: 0.92, b: 0.59,

P < 0.001) and HCV-4 (R2: 0.77, b: 0.33, P < 0.005) and conversely

diminished for HCV-3 (R2: 0.94, b: −0.82, P < 0.001). In summary, the

prevalence of HCV-1 and HCV-4 has increased over the last decade in

HIV/HCV-coinfected patients, whereas conversely it has declined for HCV-3, in

association with the wider use of HCV therapy (41%) in this population.

Document Type: Research article

DOI: 10.1111/j.1365-2893.2010.01309.x

Affiliations:1: Department of Infectious Diseases & CIBERehd, Hospital

III, Madrid, Spain 2: Research Unit, Instituto de Salud III, Majadahonda,

Spain 3: Pharmacy Unit, Hospital III, Madrid, Spain

Publication date: 2011-05-01

[Guest guest]

http://www.ingentaconnect.com/content/bsc/jvh/2011/00000018/00000005/art00003

Journal of Viral Hepatitis, Volume 18, Number 5

Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV

genotypes in HIV/HCV-coinfected patients

Authors: Medrano, J.1; Resino, S.2; Vispo, E.1; Madejón, A.1; Labarga, P.1;

Tuma, P.1; Martín-Carbonero, L.1; Barreiro, P.1; -Novoa, S.3;

Jiménez-Nacher, I.3; Soriano, V.1

Source: Journal of Viral Hepatitis, Volume 18, Number 5, May 2011 , pp.

325-330(6)

Publisher: Wiley-Blackwell

Abstract:

Summary. 

The efficacy of current hepatitis C therapy in HIV/HCV-coinfected patients is

largely dependent on HCV genotype. The annual prevalence of HCV

genotypes/subtypes and their influence on HCV clearance with antiviral treatment

were examined in a dynamic cohort of HIV/HCV-coinfected patients followed up in

Madrid since 2000. Patients entered the cohort at first visit and left the

cohort when HCV clearance was achieved with HCV therapy or when follow-up was

interrupted for any reason, including death. A total of 672 HIV/HCV-coinfected

patients constituted the cohort. The mean follow-up time was 5.5 years,

corresponding to 4108 patient-years. Mean age at entry was 37 years, and 73%

were men and 86% were intravenous drug users. Overall distribution of HCV

genotypes was as follows: 57.1% HCV-1 (1a: 29.2%, 1b: 20.4%, unknown: 7.6%),

1.3% HCV-2, 25.4% HCV-3 and 15.9% HCV-4. A total of 274 (40.8%) patients were

treated with peginterferon-ribavirin, of whom 116 (42.3%) achieved HCV clearance

following 1-3 courses of therapy. The proportion of HCV-1/4 rose from 71.7% in

2000 to 76.8% in 2008, whereas the proportion of HCV-2/3 fell from 28.1% in 2000

to 23.2% in 2008. The yearly prevalence increased for HCV-1 (R2: 0.92, b: 0.59,

P < 0.001) and HCV-4 (R2: 0.77, b: 0.33, P < 0.005) and conversely

diminished for HCV-3 (R2: 0.94, b: −0.82, P < 0.001). In summary, the

prevalence of HCV-1 and HCV-4 has increased over the last decade in

HIV/HCV-coinfected patients, whereas conversely it has declined for HCV-3, in

association with the wider use of HCV therapy (41%) in this population.

Document Type: Research article

DOI: 10.1111/j.1365-2893.2010.01309.x

Affiliations:1: Department of Infectious Diseases & CIBERehd, Hospital

III, Madrid, Spain 2: Research Unit, Instituto de Salud III, Majadahonda,

Spain 3: Pharmacy Unit, Hospital III, Madrid, Spain

Publication date: 2011-05-01